Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology

Circulation

Volumn 132, Issue 22, 2015, Pages e310-e314

  Thompson, Paul D ^a   Myerburg, Robert J ^b   Levine, Benjamin D ^c   Udelson, James E ^d   Kovacs, Richard J ^e  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

AHA Scientific Statements; athletes; coronary artery disease; sudden cardiac death

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ARTICLE; ATHLETE; CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR RISK; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CORONARY ARTERY DISSECTION; CORONARY ARTERY SPASM; CORONARY ARTERY THROMBOSIS; CORONARY VASCULITIS; CORONARY VASCULOPATHY; EXERCISE TOLERANCE; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIAL BRIDGING; PRIORITY JOURNAL; SILENT MYOCARDIAL ISCHEMIA; SPONTANEOUS CORONARY ARTERY DISSECTION; VASCULAR DISEASE; ADVISORY COMMITTEE; CARDIOLOGY; CARDIOVASCULAR ABNORMALITIES; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; UNITED STATES;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; ATHLETES; CARDIOLOGY; CARDIOVASCULAR ABNORMALITIES; CORONARY ARTERY DISEASE; HUMANS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84949316474     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000244     Document Type: Article

References (18)

1. Parker MW, Thompson PD. Assessment and management of atherosclerosis in the athletic patient. Prog Cardiovasc Dis. 2012;54:416-422. doi: 10.1016/j.pcad.2012.02.001.
2. Van Hare GF, Ackerman MJ, Evangelista JK, Kovacs RJ, Myerburg RJ, Shafer KM, Warnes CA, Washington RL; on behalf of the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and the American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 4: congenital heart disease: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e281-e291. doi: 10.1161/CIR.0000000000000240.
3. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009;50(suppl):S352-S357. doi: 10.1194/jlr.R800099-JLR200.
4. Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif JC, Brener SJ, Cain VA, Nissen SE; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458-2466. doi: 10.1161/CIRCULATIONAHA.108.773747.
5. Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, Lane T, Neradilek MB, Polissar N, Monick D, Lee C, Underhill H, Yuan C. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging. 2011;4:977-986. doi: 10.1016/j.jcmg.2011.06.013.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;129(suppl 2):S46-S48]. Circulation. 2014;129(suppl 2):S1-S45. doi: 10.1016/01. cir.0000437738.63853.7a.
7. Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K. Long-term prognosis for patients with variant angina and influential factors. Circulation. 1988;78:1-9.
8. Lanza GA, Sestito A, Sgueglia GA, Infusino F, Manolfi M, Crea F, Maseri A. Current clinical features, diagnostic assessment and prognostic determinants of patients with variant angina. Int J Cardiol. 2007;118:41-47. doi: 10.1016/j.ijcard.2006.06.016.
9. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries: the ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012;59:655-662. doi: 10.1016/j.jacc.2011.11.015.
10. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J, Gardner M, Sanatani S, Exner DV, Klein GJ, Yee R, Skanes AC, Gula LJ, Gollob MH. Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) [published correction appears in Circulation. 2010;121:e460]. Circulation. 2009;120:278-285. doi: 10.1161/CIRCULATIONAHA.109.853143.
11. Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H; Japanese Coronary Spasm Association. Clinical characteristics and long-term prognosis of vasospastic angina patients who survived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295-302. doi: 10.1161/CIRCEP.110.959809.
12. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, deMarchena E, Interian A Jr, Castellanos A. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med. 1992;326:1451-1455. doi: 10.1056/NEJM199205283262202.
13. Kalaga RV, Malik A, Thompson PD. Exercise-related spontaneous coronary artery dissection: case report and literature review. Med Sci Sports Exerc. 2007;39:1218-1220. doi: 10.1249/mss.0b013e318060114f.
14. Michelis KC, Olin JW, Kadian-Dodov D, d'Escamard V, Kovacic JC. Coronary artery manifestations of fibromuscular dysplasia. J Am Coll Cardiol. 2014;64:1033-1046. doi: 10.1016/j.jacc.2014.07.014.
15. Baggish AL, Thompson PD. The Athlete's Heart 2007: diseases of the coronary circulation. Cardiol Clin. 2007;25:431-40, vi. doi: 10.1016/j. ccl.2007.07.003.
16. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease: a 10-to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379-1385.
17. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888-893.
18. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [published correction appears in Pediatrics. 2005;115:1118]. Pediatrics. 2004;114:1708-1733. doi: 10.1542/peds.2004-2182.